Advertisement

Topics

AstraZeneca Hopes Imfinzi Breakthrough Get Can Burn Off MYSTIC Failure

19:49 EDT 31 Jul 2017 | Elsevier Business Intelligence

Imfinzi becomes first cancer immunotherapy designated a breakthrough therapy for non-metastatic non-small cell lung cancer pa...

Original Article: AstraZeneca Hopes Imfinzi Breakthrough Get Can Burn Off MYSTIC Failure

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca Hopes Imfinzi Breakthrough Get Can Burn Off MYSTIC Failure"

Quick Search
Advertisement
 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...